ISTITUTO ZOOPROFILATTICO SPERIMENTALE DELLE VENEZIE
ISTITUTO ZOOPROFILATTICO SPERIMENTALE DELLE VENEZIE
L E G N A R O (PD)
D E L D I R E T T O R E G E N E R A L E
N. 405 del 21/12/2022
OGGETTO: Approvazione dello schema di ``Biological Material Transfer Agreement for research purposes in the veterinary field only`` tra l`Istituto Zooprofilattico Sperimentale delle Venezie e il Roslin Institute - University Court of the University of Edinburgh.
Atto sottoscritto digitalmente ai sensi del D.Lgs. 82/2005 s.m.i. e norme collegate e sostituisce il documento cartaceo e la firma autografa
ISTITUTO ZOOPROFILATTICO SPERIMENTALE DELLE VENEZIE
L E G N A R O (PD)
DELIBERAZIONE DEL DIRETTORE GENERALE
OGGETTO: Approvazione dello schema di ``Biological Material Transfer Agreement for research purposes in the veterinary field only`` tra l`Istituto Zooprofilattico Sperimentale delle Venezie e il Roslin Institute - University Court of the University of Edinburgh.
Si sottopone al Direttore generale la seguente relazione del Responsabile della S.S. Affari Generali, Anticorruzione e Trasparenza.
Si premette che:
- ai sensi dell’art. 1, comma 6, del D.Lgs. n. 270/1993 e dell’art. 9, comma 2, del D.Lgs. n. 106/2012 “Gli Istituti, in relazione allo svolgimento delle loro competenze, possono stipulare convenzioni o contratti di consulenza per la fornitura di servizi e per l’erogazione di prestazioni ad enti, associazioni, organizzazioni pubbliche e private, sulla base di disposizioni regionali […]”;
- l’Istituto Zooprofilattico Sperimentale delle Venezie, nel quadro dei propri compiti istituzionali – di cui all’art. 3, dell’Accordo sulla gestione dell’IZSVe approvato dalla Regione del Veneto, dalla Regione Autonoma Friuli Venezia Giulia e dalle Province Autonome di Trento e Bolzano, rispettivamente, con Leggi n. 5/2015, n. 9/2015, n. 5/2015 e n. 5/2015 – provvede all’effettuazione di ricerche di base e finalizzate per lo sviluppo delle conoscenze nell’igiene e sanità veterinaria, nella sicurezza alimentare e nutrizione, secondo programmi e anche mediante convenzioni con università e istituti di ricerca italiani e stranieri, nonché su richiesta dello Stato, delle Regioni, delle Province autonome e di enti pubblici e privati;
- tra le finalità istituzionali dell’IZSVe rientra, pertanto, la realizzazione di attività di ricerca sanitaria che richiede la stipulazione dei correlati atti contrattuali, tra cui rientrano anche i cd. “Accordi per il trasferimento di materiale biologico”, accordi finalizzati allo
Atto sottoscritto digitalmente ai sensi del d.lgs. 82/2005 s.m.i. e norme collegate e sostituisce il documento cartaceo e la firma autografa
Pagina 1 di 5
X.X.X.Xx – Deliberazione del DIRETTORE GENERALE
scambio di materiale per scopi di ricerca, con i quali vengono definiti i diritti del Fornitore e i diritti ed obblighi del Ricevente rispetto al Materiale, Derivati e Modifiche;
- tali accordi assolvono, quindi, l’esigenza di procurarsi materiali indispensabili per poter svolgere una fondata attività di ricerca ponendo le basi per un’eventuale futura collaborazione tra le parti;
- con mail dell’1.04.2022, il Roslin Institute – istituto di ricerca, parte dell’Università di Edimburgo, il cui obiettivo è migliorare la salute degli animali e degli esseri umani attraverso la ricerca sulla biologia animale – ha richiesto all’IZSVe di addivenire alla stipula di un Accordo per il trasferimento di materiale biologico a scopo di ricerca, consistente in ceppi di Streptococcus uberis isolati da latte raccolto da bovine affette da mastite, allo scopo di eseguire test di sensibilità antimicrobica;
- con DDG n. 365/2022 è stato approvato lo schema standard di “Accordo per il trasferimento di materiale biologico a scopo di ricerca (MTA) in campo veterinario” nelle versioni in lingua italiana e in lingua inglese, prevedendo che lo stesso possa essere derogato, di comune accordo tra le parti, per ragioni di opportunità e convenienza, a seguito di apposita istruttoria e formale provvedimento di approvazione.
Considerato che il Roslin Institute, per lo svolgimento delle suddette attività di ricerca – in particolare per il sequenziamento del genoma del materiale biologico – si avvarrà della collaborazione di terzi, le Parti hanno provveduto a concordare le revisioni allo schema standard di “Biological Material Transfer Agreement for research purposes in the veterinary field only”, la cui versione definitiva si allega al presente provvedimento quale parte integrante e sostanziale (allegato n. 1).
Con ticket intranet n. 189116/2022, la dott.ssa Xxxxxx Xxxxx, dirigente biologo presso il “Laboratorio batteriologia speciale” della “SCT2 – Treviso, Belluno e San Donà di Piave” ha richiesto alla scrivente Struttura di procedere con gli adempimenti necessari alla stipula dell’Accordo in parola.
Con il predetto Accordo – efficace dalla data di ultima sottoscrizione per un periodo di 18 mesi e comunque fino a quando non vengano terminate le attività di ricerca – l’IZSVe si impegna a fornire a titolo gratuito il materiale biologico, specificamente descritto all’art. 1 dell’Accordo stesso, al Roslin Institute, che sosterrà le spese di spedizione in qualità di parte Ricevente.
Tutto ciò premesso, sulla base degli elementi riportati dal referente dell’istruttoria, si propone al Direttore generale quanto segue:
1. di approvare lo schema di “Biological Material Transfer Agreement for research purposes in the veterinary field only”, da sottoscrivere tra l’Istituto Zooprofilattico Sperimentale delle Venezie, rappresentato dal Direttore Generale e legale rappresentante pro tempore, dott.ssa Xxxxxxx Xxxxx, e il Roslin Institute – University Court of the University of Edinburgh, rappresentato dalla dott.ssa Xxxxx X. Xxxxxxx, documento che si allega al presente provvedimento quale parte integrante e sostanziale (allegato n. 1);
2. di procedere, per l’effetto, alla sottoscrizione dell’Accordo di cui al punto che precede, ai sensi degli artt. 15 e 16 del vigente Accordo interregionale sulla gestione dell’Istituto Zooprofilattico Sperimentale delle Venezie, sottoscrizione che avverrà con firma
Atto sottoscritto digitalmente ai sensi del d.lgs. 82/2005 s.m.i. e norme collegate e sostituisce il documento cartaceo e la firma autografa
Pagina 2 di 5
X.X.X.Xx – Deliberazione del DIRETTORE GENERALE
digitale ai sensi dell’art. 15, comma 2-bis della L. n. 241/1990, come modificato dall’art. 6, comma 5, del D.L. n. 145/2013, convertito, con modificazioni, dalla Legge n. 9/2014;
3. di prendere atto che l’Istituto con il predetto Accordo – efficace dalla data di ultima sottoscrizione per un periodo di 18 mesi e comunque fino a quando non vengano terminate le attività di ricerca – si impegna a fornire il materiale indicato all’art. 1 a titolo gratuito, salvo il costo per le spese di spedizione che saranno a carico del Roslin Institute, in qualità di parte Ricevente.
ESAMINATA la proposta di deliberazione del Responsabile della S.S. Affari Generali, Anticorruzione e Trasparenza che attesta la regolarità della stessa in ordine ai contenuti sostanziali, formali e di legittimità dell’atto, attestazione allegata al presente provvedimento.
VISTO il decreto del Presidente della Giunta regionale del Veneto n. 102 del 22 settembre 2020 con il quale è stata nominata la dott.ssa Xxxxxxx Xxxxx quale Direttore generale dell’Istituto Zooprofilattico Sperimentale delle Venezie.
VISTA la delibera del Direttore generale n. 372 del 14 ottobre 2020 con la quale la dott.ssa Xxxxx Xxxxxxx è stata nominata Direttore sanitario dell’Istituto.
VISTA la delibera del Direttore generale n. 101 del 10 marzo 2021 con la quale il xxxx.
Xxxxxxx Xxxxxx è stato nominato Direttore amministrativo dell’Istituto.
ACQUISITO il parere favorevole del Direttore amministrativo e del Direttore sanitario per quanto di competenza, espresso ai sensi dell’art. 15 dello Statuto dell’Istituto, adottato con delibera del CdA n. 12 del 24 maggio 2021 e approvato con delibera della Giunta regionale del Veneto n. 1308 del 28 settembre 2021.
VISTO l’Accordo per la gestione dell’Istituto Zooprofilattico Sperimentale delle Venezie tra la Regione del Veneto, la Regione Autonoma Friuli Venezia Giulia e le Province Autonome di Trento e Bolzano, approvato dai suddetti Enti, rispettivamente, con leggi n. 5/2015, n. 9/2015, n. 5/2015 e n. 5/2015.
1. di approvare lo schema di “Biological Material Transfer Agreement for research purposes in the veterinary field only”, da sottoscrivere tra l’Istituto Zooprofilattico Sperimentale delle Venezie, rappresentato dal Direttore Generale e legale rappresentante pro tempore, dott.ssa Xxxxxxx Xxxxx, e il Roslin Institute – University Court of the University of Edinburgh, rappresentato dalla dott.ssa Xxxxx X. Xxxxxxx, documento che si allega al presente provvedimento quale parte integrante e sostanziale (allegato n. 1);
2. di procedere, per l’effetto, alla sottoscrizione dell’Accordo di cui al punto che precede, ai sensi degli artt. 15 e 16 del vigente Accordo interregionale sulla gestione dell’Istituto Zooprofilattico Sperimentale delle Venezie, sottoscrizione che avverrà con firma
Atto sottoscritto digitalmente ai sensi del d.lgs. 82/2005 s.m.i. e norme collegate e sostituisce il documento cartaceo e la firma autografa
Pagina 3 di 5
X.X.X.Xx – Deliberazione del DIRETTORE GENERALE
digitale ai sensi dell’art. 15, comma 2-bis della L. n. 241/1990, come modificato dall’art. 6, comma 5, del D.L. n. 145/2013, convertito, con modificazioni, dalla Legge n. 9/2014;
3. di prendere atto che l’Istituto con il predetto Accordo – efficace dalla data di ultima sottoscrizione per un periodo di 18 mesi e comunque fino a quando non vengano terminate le attività di ricerca – si impegna a fornire il materiale indicato all’art. 1 a titolo gratuito, salvo il costo per le spese di spedizione che saranno a carico del Roslin Institute, in qualità di parte Ricevente.
Il presente provvedimento non è soggetto al controllo previsto dall’Accordo per la gestione dell’Istituto Zooprofilattico Sperimentale delle Venezie approvato dagli Enti cogerenti con le leggi regionali e provinciali citate nelle premesse.
IL DIRETTORE GENERALE
dott.ssa Xxxxxxx Xxxxx
Sul presente atto deliberativo ha espresso parere favorevole
Il Direttore amministrativo Il Direttore sanitario
xxxx. Xxxxxxx Xxxxxx dott.ssa Xxxxx Xxxxxxx
Atto sottoscritto digitalmente ai sensi del d.lgs. 82/2005 s.m.i. e norme collegate e sostituisce il documento cartaceo e la firma autografa
Pagina 4 di 5
X.X.X.Xx – Deliberazione del DIRETTORE GENERALE
ATTESTAZIONI ALLEGATE ALLA DELIBERAZIONE DEL DIRETTORE GENERALE
Il Responsabile della Struttura proponente attesta la regolarità della proposta di deliberazione, presentata per l’adozione, in ordine ai contenuti sostanziali, formali e di legittimità dell’atto e che la stessa:
Comporta spesa 🞏 su Finanziamento istituzionale 🞏
Finanziamento vincolato 🞏
Altri finanziamenti 🞏
Non comporta spesa ⌧
ATTESTAZIONE DI COPERTURA ECONOMICA DELLA SPESA
Il Responsabile del Budget attesta l’avvenuto controllo sulla disponibilità di budget
Evidenziato infine che il responsabile della Struttura proponente, con la sottoscrizione della proposta di cui al presente atto, dichiara, sotto la propria responsabilità ed ai sensi e agli effetti degli artt. 47 e 76 del dPR 28 dicembre 2000, n. 445, che, in relazione alla presente procedura, non si trova in condizioni di incompatibilità di cui all’art. 35 bis del d.lgs. n. 165/2001, né sussistono conflitti di interesse di cui all’art. 6 bis della legge n. 241/1990 e agli artt. 6, 7 e 14 del dPR n. 62/2013.
dott.ssa Xxxxxx Xxxxxxxx
Atto sottoscritto digitalmente ai sensi del d.lgs. 82/2005 s.m.i. e norme collegate e sostituisce il documento cartaceo e la firma autografa
Pagina 5 di 5
ISTITUTO ZOOPROFILATTICO SPERIMENTALE DELLE VENEZIE
Viale dell’Università 10 – 00000 XXXXXXX (XX)
DELIBERAZIONE DEL DIRETTORE GENERALE N. 405 del 21/12/2022
OGGETTO: Approvazione dello schema di ``Biological Material Transfer Agreement for research purposes in the veterinary field only`` tra l`Istituto Zooprofilattico Sperimentale delle Venezie e il Roslin Institute - University Court of the University of Edinburgh.
Pubblicata dal 21/12/2022 al 05/01/2023 Atto immediatamente esecutivo
Il Responsabile della Pubblicazione Xxxxx Xxxxxxx
Elenco firmatari
Questo documento è stato firmato da:
Dott.ssa Xxxxxx Xxxxxxxx - Servizio Affari generali, anticorruzione e trasparenza Xxxx. Xxxxxxx Xxxxxx - Direzione Amministrativa
Dott.ssa Gioia Capelli - Direzione Sanitaria Dott.ssa Xxxxxxx Xxxxx - Direzione Generale Xxxxx Xxxxxxx - Xxxxxxxx Atti
BIOLOGICAL MATERIAL TRANSFER AGREEMENT
FOR RESEARCH PURPOSES IN THE VETERINARY FIELD ONLY
Istituto Zooprofilattico Sperimentale delle Venezie, is a public veterinary Institute with offices at Xxxxx xxxx’Xxxxxxxxxx 00, 00000 Xxxxxxx (XX), Xxxxx, fiscal code and VAT n. 00206200289, acting by Dr. Xxxxxxx Xxxxx, in her capacity as Director General, hereinafter referred to as “IZSVe” or “Provider”
and
The University Court of the University of Edinburgh, acting through its Roslin Institute, having a place of business at Easter Bush Campus, Midlothian, XX00 0XX, Xxxxxxxx, XX, represented by its Senior Legal Advisor, Xxxxx X. Xxxxxxx, Hereinafter referred to as “Recipient”
and severally as “Party” and jointly as “ Parties”
This Agreement sets out the understanding of the Parties with respect to the provision of certain biological material to the Recipient, which wishes to use the material for non-commercial evaluation purposes only subject to the terms and conditions of this Agreement.
WHEREAS:
• The mission of the IZSVe is to monitor and preserve animal welfare and to control the animal and plant origin food-production chain; it is also involved in experimental research projects embracing the veterinary field;
• The IZSVe is involved in current research projects in collaboration with national and international organizations that aim at strengthening the existing knowledge in the field of veterinary hygiene and animal welfare, food safety and nutrition;
• The Recipient aims to enhance the lives of animals and humans through world class research in animal biology. It is engaged in various strands of research within this overall field;
IZSVe agrees to transfer to Recipient the following biological material only for research purposes in compliance with the clauses of the present Agreement
NOW, THEREFORE,
in consideration of the covenants and obligations hereinafter set forth, the Parties hereto, individually and by their respective agents and representatives, hereby agree as follows:
ART. 1. DEFINITIONS
The below mentioned words have the following meanings in this Agreement:
“Effective date”: the date as of which the Agreement enters into force.
“Commercial Purposes”: the application of patent to the Material and/ or Modifications, the sale of products or services, lease, license, or other transfer of the Material or Modifications for any commercial purpose or for the direct benefit of any for-profit entity, including use of the Material or Modifications by any organization, including Recipient, to perform research for third parties who obtain rights in research results, to screen compounds, to produce or manufacture products for general sale, or to conduct any research activities that result in any sale, lease, license, or transfer of the Material or Modifications to a for-profit entity. For the avoidance of doubt, Commercial Purposes shall not include transfer of the Material to MicrobesNG for sequencing, as further described in Annex 1.
“Confidential Information”: Information of a confidential nature protected or not by an intellectual property right (for example data, documents, methods, know-how, etc.) whatever their subject, transmission mode, origin, communicated by one Party (the “Disclosing Party”) to the other (the “Receiving Party”) within the frame of this Agreement. The Material is Confidential Information. Confidential information does not include information that:
a) is a part of the public domain at the last date of signature of this Agreement or becomes publicly available other than through an unauthorised disclosure by the Receiving Party;
b) can be demonstrated was already known by the Receiving Party at the time of disclosure by the Disclosing Party;
c) is disclosed to the Receiving Party and explicitly defined by the Disclosing Party as non-confidential;
d) the Receiving Party can demonstrate has been independently developed by the Receiving Party without using any of the Confidential Information of the Disclosing party;
e) is revealed to the Receiving Party by someone other than the Disclosing Party who has no obligation to secrecy under the terms and conditions of the present Agreement; or else, information which is disclosed to the Recipient Party by any other means not ascribable to the present Agreement;
f) is required by law, regulation, rule, act or order of any governmental authority or agency to be disclosed by the Receiving Party, provided, however, that where it is possible to do so, such Receiving Party (A) gives the Disclosing Party sufficient advance written notice to permit it to seek a protective order or other similar order with respect to such Confidential Information and (B) thereafter discloses only the minimum information required to be disclosed in order to comply, whether or not a protective order or other similar order is obtained by such Disclosing Party;
g) has been previously agreed in written form by the provider of such information is not confidential.
“Original Material”: the Material to be delivered from IZSVe to the Recipient under the term of this Agreement is as below specified.
Microorganism/ Other biological material | Isolate ID Sample type | Year of isolation/Samp le Collection date | Species | Substrate of Isolation | Comments | Quantity |
Microorganisms | S. uberis | 2021 | Streptococcus uberis | Milk | Isolates from milk collected from bovine affected by clinical or subclinical mastitis | 200 |
“Material”: Original Material, Progeny, Unmodified Derivatives, (but does not include Modifications or other substances created by the Recipient through the use of the Material)
“Progeny”: an unmodified descendant from the Original Material, such as virus from virus, cell from cell, or organism from organism.
“Unmodified Derivatives”: any unmodified functional subunit or product expressed by the Original Material (for example subclones of unmodified cell lines, purified or fractionated subsets of the Original Material, proteins expressed by DNA/RNA supplied by the Provider, or monoclonal antibodies secreted by a hybridoma cell line).
“Modifications”: substances created by the Recipient which contain or incorporate Material, such as homologous recombination products, germ line transmission products, crossover products, novel varieties, cell fusion, sub-clonation products, etc.
“Patent Rights”: any patents, patent applications, trade secrets or other proprietary rights of the Provider having claims relating to the Original Material, including any altered forms of the Material made by the Provider, and any substitutions, divisions, continuations, continuations-in-part, reissues, renewals, registrations, confirmations, re-examinations, extensions, supplementary protection certificates or the like, or provisional applications of any such patents and patent applications, or foreign equivalents thereof.
“Provider's Scientist”: the employees of IZSVe.
“Recipient’s scientist”: the employees of the Recipient.
“Research activities”: (described in Annex 1) description of the experiments planned with the Material.
ART. 2. MATERIAL TRANSFER
IZSVe shall supply the Recipient with the Material within thirty (30) days after the execution of this Agreement by both Parties.
The Recipient will contact IZSVe, in particular the Provider’s scientist, to arrange the date(s) of shipment. Subject to the terms and conditions herein, the Provider grants to the Recipient a royalty-free, non-exclusive license to use the Material solely in performance of the Research activities described in Annex 1 – Description of activities.
The Recipient agrees that the Material:
a) will not be used for Commercial Purposes; any commercial use of the Material is strictly forbidden. The Recipient undertakes not to sell, disclose, transfer, give or distribute the Material to any third party except that IZSVe hereby agrees that the Recipient may transfer Material to MicrobesNG for genomic sequencing, as further described in Annex 1, in accordance with MicrobesNG’s terms and conditions;
b) will not be used in human subjects, in clinical trials, or for diagnostic purposes involving human subjects without the Provider's prior written consent;
c) will be used only at the Recipient organization and only in the Recipient's Scientist’s laboratories under the direction of the Recipient’s Scientist or others working under his or her direct supervision, except that XXXXx xxxxxx agrees that the Recipient may also transfer Material to MicrobesNG for sequencing, as described in Annex 1, in accordance with MicrobesNG’s terms and conditions;
d) will not be further transferred without the Provider's prior written consent.
The Recipient will refer any request for the Material from anyone other than those persons working under the Recipient’s Scientist's direct supervision to the Provider's Scientist.
Upon request, the Recipient will provide IZSVe with a summary of the Research Activities obtained with the Material. IZSVe hereby agrees to treat any such summary as Confidential Information of the Recipient and not to disclose it to any third parties or use it for any purpose, without first obtaining the Recipient’s written consent. The Recipient will use the Material and Modifications in compliance with all applicable laws and governmental regulations and guidelines applicable to the Material and Modifications.
The Recipient shall ensure that the Recipient's employees, students and agents using the Material and Modifications agree to be bound by the terms of this Agreement.
ART. 3. FEE AND PAYMENT
The Material for the Research activities is provided for free. Shipping costs will be charged on the Recipient. ART. 4. USE OF THE MATERIAL AND INTELLECTUAL PROPERTY
The Material is owned by the Provider who maintains the ownership of the Material, (including any Material contained or incorporated in Modifications).
The transfer does not grant or imply the ownership of the Material, or any intellectual and industrial property rights to the Recipient.
Results generated by the Recipient through its use of the Material in the Research Activities (“Results”) shall be owned by the Recipient, except that the Provider retains ownership of any Material contained or incorporated therein.
Recipient shall use, and shall cause its researchers to use, the Materials in compliance with all applicable laws, regulations, guidelines and recommendations issued by national and international body applicable to the Material, and according to the terms and conditions set out in the previous art 2. In particular Recipient shall use the Material in compliance with ethical laws, the research shall be conducted in accordance with the national and international ethical guidelines related to the use of animals in research.
The Material may be used on animals only if such use is explicitly approved by an Ethics Committee or by the legislation on the treatment of laboratory animals.
The Material will be used by the Recipient solely and strictly in connection with performing the Research activities. The Research activities will take place at Recipient’s institutional facilities and at MicrobesNG’s sequencing facilities and will be under the direction of Recipient’s Scientist.
No rights are provided to Recipient under any patent applications, trade secrets or other proprietary rights of IZSVe. In particular, no rights are provided to use the Material or Modifications for profit-making or commercial purposes, or provision of a commercial service based upon the Material or Modifications. The Material shall not be incorporated into any service or product for sale, or used for the commercial provision. For the avoidance of doubt, this Article 4 shall not prevent the Recipient transferring Material to MicrobesNG to carry out the Research activities.
If Recipient desires to use the Material or Modifications for such profit-making or commercial purposes, Recipient agrees that it must first negotiate a license or other appropriate Agreement with IZSVe and third parties as may be required, and it is further understood by Recipient that IZSVe shall have no obligation to enter into such a license or agreement.
The Recipient may distribute substances created by the Recipient through the use of the Original Material only if those substances are not Progeny or Unmodified Derivatives. Modifications may be distributed by the Recipient only with prior written notice to the Provider.
If the Recipient wishes to submit a patent on Results which contain the Material referred to in this Agreement, it must first obtain the prior written consent of IZSVe (such consent not to be unreasonably withheld). The discipline of the patent will therefore be regulated by a specific separate agreement between the Parties.
ART. 5. LIABILITY
All Material provided within the framework of the present Agreement are to be used for experimental purposes. By requesting the Material and signing this Agreement, the Recipient accepts responsibility for the proper handling and testing of the Material and Modifications in accordance with generally accepted international scientific standards, including any disposition and guidelines regarding biosecurity, biosafety, health and scientific research. The Recipient guarantees that suitable handling and containment conditions are available and will be applied in the Recipient’s laboratory.
The Recipient accepts that the Material and any Progeny classified as Risk Group 2 (as defined by EU Regulations on such matters) includes known pathogens and that any other Material, differently identified, may be pathogenic under certain conditions.
The Recipient represents that within its laboratories, the access to the Material and to Modifications will be restricted to personnel capable and qualified to safely handle those substances, using appropriate containment.
The Recipient shall use the appropriate precaution to minimise any risk of harm to persons and property and to safeguard them from theft or misuse.
Except to the extent prohibited by law, the Recipient assumes all liability for damages which may arise directly from its use, storage or disposal of the Material. The Provider will not be liable to the Recipient for any loss, claim or demand made by the Recipient, or made against the Recipient by any other party, due to or arising from the use of the Material by the Recipient, except to the extent permitted by law when caused by the gross negligence or willful misconduct of the Provider.
The Provider does not guarantee that the use of the Material does not violate any patent, trademark or any other property right of any third party.
ART. 6. WARRANTY
The Recipient acknowledges that the Material are supplied to the Recipient with no information on their use, warranties, express or implied, including but not limited to any warranty of fitness for a particular purpose.
However IZSVe represents and warrants to the Recipient that its execution of this Agreement will not result in a breach of any obligation to any third party or infringe or otherwise violate any third party’s rights. There are no express or implied warranties that the Material and/or Modifications will not pose a safety or health risk.
If the Material is not available for use or not delivered in sufficient amounts, the Recipient shall send a written notification to IZSVe within ten (10) days after the receipt of the Material (or in case non-delivery of Material, within ten (10) days of the agreed date of shipment). In these cases, IZSVe shall replace the Material only. This warranty is valid if the Recipient ensures that the Material has been stored or processed as indicated in the documents that will accompany it.
ART. 7. TERM AND TERMINATION
This Agreement shall be effective upon full execution and shall remain in force for a period of 18 months or until the Recipient’s Research activities have been completed using the requested Material, whichever is longer. Either Party may terminate this Agreement by written notice to the other Party, whereupon the Agreement will terminate 30 days after written notice thereof from the terminating Party. Termination of this Agreement shall not affect any obligations that came into or continue in effect on or following termination.
The withdrawal must be communicated to the other Party by registered letter with return receipt.
In the event of termination of this Agreement, the Recipient will have to interrupt the ongoing activities carried out with the use of the Material and, following the IZSVe indications, will have to return or destroy the Material, and any confidential information referring to the Material itself.
This Agreement will be terminated without notice should the Recipient violate the terms of this Agreement. In this case, the termination will become effective from when awareness of the violation is acknowledged in writing by IZSVe to the Recipient.
On expiry or termination of this Agreement, the Material and IZSVe’s confidential information referring to the Material must be disposed of or returned to the IZSVe. The Recipient may retain Results generated by it under this Agreement, including any Modifications, but shall continue to be bound by the terms of Article 4, insofar as these terms apply to Modifications.
ART. 8. MISCELLANEOUS
Confidential information: The Recipient shall not give, sell, share, release, convey, or otherwise distribute the Material and/or any accompanying Confidential Information to any third party without the prior written permission of IZSVe. The Recipient acknowledges that IZSVe may withhold its consent for any reason it deems necessary and is not obliged to give the reason thereof.
Confidential Information of either Party will be safeguarded and not disclosed to any third parties by the Receiving Party. The Recipient also undertakes to retain in confidence and not, other than as expressly permitted under this Agreement, disclose to any third party the Material.
The Recipient may disclose, with prior written permission, the Provider’s Confidential Information to the Recipient’s parent corporations, affiliates and subsidiaries only if such parent corporations, affiliates and subsidiaries agree to be bound by confidentiality and non-use provisions at least as protective of the Provider’s rights as those contained in this Agreement.
In the event that either Party is requested or required by law or legal process to disclose any of the Confidential Information, the Receiving Party shall endeavor to provide the Disclosing Party with prompt written notice before making any disclosure. In addition, Confidential Information may be disclosed to the extent required in the course of inspections or inquiries by EU Federal or State regulatory agencies to whose jurisdiction IZSVe and/or the Recipient is/are subject to and that has/have the legal right to inspect documents containing the Confidential Information. The Recipient shall promptly advise IZSVe upon such disclosure and vice versa.
Publication: The Recipient is free to release scientific publications concerning the outcomes of the scientific research carried out with the Material. Every publication referring to the Material and Modification shall acknowledge the source of the Material, giving the due reference to IZSVe.
Force Majeure: Neither the IZSVe nor the Recipient will be held responsible for the failure, the inaccurate or delayed fulfillment of the obligations of this Agreement, where the same has been caused, directly or indirectly, by unforeseeable circumstances, force majeure or any other cause not attributable to the same.
In the event of such force majeure, the affected Party shall promptly notify the other Party in writing. If the force majeure lasts more than ninety (90) days, the other Party shall have the right to terminate the Agreement; the notice of termination shall be made according to the present article 8.
Governing Law: This Agreement shall be governed by the laws of the Party against which a legal or administrative proceeding (for example litigation, arbitration or mediation) is brought. The Parties shall endeavor to settle any dispute in connection with the interpretation or performance of this agreement by amicable arrangement. In the event of continuing disagreement, the Parties shall refer the dispute to the courts of the general place of jurisdiction of the defending Party.
Entire Agreement: This Agreement constitutes the entire understanding of the Parties with respect to the matters contained herein, superseding all prior oral or written understandings or communications between the Parties relating to the present Agreement. This Agreement may be amended, modified, superseded or canceled, only by a written instrument executed by each Party’s duly authorized representatives.
Assignment: This Agreement and the rights, obligations and duties set forth herein may not be assigned, transferred, delegated or sub-contracted by the Recipient without the prior written consent of the IZSVe.
Notices: All notices and communications related to this Agreement shall be made by registered or certified letter, return receipt requested, telecopier or electronic transmission confirmed in writing by registered mail and shall be addressed as follows (or to other address as may hereafter be designed by written notice):
If to IZSVe: Att. Dr. Xxxxx Xxxxxx xxxxxx@xxxxxxxxxx.xx
If to the Recipient: Att. Roslin Legal Team, Roslin Institute, Easter Bush Campus, Midlothian, XX00 0XX, Xxxxxxxx, XX. Please quote reference R3213.
ART. 9. NEGOTIATION
This Agreement has been freely negotiated between the Parties hereto and represents their willingness as duly and clearly shown in the content hereof and properly considered.
IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed by their duly authorised representatives as of the day and year first above written.
This Agreement is made at the date and place of the last signature.
Edinburgh, (date) Legnaro, (date)
The University Court of the University of
Edinburgh, acting through its Roslin Institute Istituto Zooprofilattico Sperimentale
delle Venezie
(Xxxxx X. Xxxxxxx, Senior Legal Advisor) (Dr. Xxxxxxx Xxxxx, Acting Director General)
Annex 1 – Description of activities
(Please briefly describe how you intend to use the material)
Perform antimicrobial sensitivities assay on isolates.
Extract genomic DNA and send this to MicrobesNG for genome sequencing. Strain, derivatives or products will not otherwise be shared.
Publish/present analysis in manuscript and at conferences including release of genome sequence data into public repositories.
Further investigation of the Material may be conducted, with IZSVe’s consent, if for example particular genes or strains prove to be of interest following the initial analyses.